Skip to main content
Top
Published in: Calcified Tissue International 1/2010

Open Access 01-01-2010

Do Estrogen and Alendronate Improve Metaphyseal Fracture Healing When Applied as Osteoporosis Prophylaxis?

Authors: Leila Kolios, Ann Kristin Hoerster, Stephan Sehmisch, Marie Christin Malcherek, Thomas Rack, Mohammed Tezval, Dana Seidlova-Wuttke, Wolfgang Wuttke, Klaus Michael Stuermer, Ewa Klara Stuermer

Published in: Calcified Tissue International | Issue 1/2010

Login to get access

Abstract

Osteoporosis is accompanied by predominantly metaphyseal fractures with a delayed and qualitatively reduced healing process. This study addressed the question of whether fracture healing in the context of osteoporosis prophylaxis is improved with estrogen (E) or alendronate (ALN). Thirty-six ovariectomized and 12 sham-operated 12-week-old rats received soy-free (osteoporotic C, sham), E-, or ALN- supplemented diets. After 10 weeks, a metaphyseal tibia osteotomy and standardized T-plate fixation were performed. After a 5-week healing process, the fracture callus was evaluated qualitatively by biomechanical bending test and quantitatively in microradiographic sections. The time course of callus formation was examined using fluorochrome-labeled histological sections. Administration of E improved the biomechanical properties of callus (stiffness [N/mm]: sham: 110.2 ± 76.07, C: 41.28 ± 33.70, E: 85.72 ± 47.24, ALN: 72.07 ± 34.68). The resistance to microfracturing seen in E-treated animals was significantly enhanced and even superior to sham (yield load [N] sham: 27.44 ± 9.72, C: 21.04 ± 12.47, E: 42.85 ± 13.74, ALN: 25.28 ± 6.4·) (* P < 0.05 vs. sham group,  P < 0.05 vs. C group,  P < 0.05 vs. E group). Trabecular bone in particular was improved, indicating the presence of physiological endosteal bridging (Tr.Dn [%] sham: 10.53 ± 18.9, C: 1.01 ± 0.14, E: 24.13 ± 34.09, ALN: 3.99 ± 8.3·). ALN did not help bone healing, as shown by mechanical tests. Compared to the C group, statistically, ALN did not show worse properties. The induction of callus formation under ALN treatment was slightly delayed (Tt.Cl [mm2] sham: 3.68 ± 0.66, C: 3.44 ± 0.42, E: 3.69 ± 0.58, ALN: 3.06 ± 0.56). Osteoporotic metaphyseal fracture healing was qualitatively and quantitatively improved by E prophylaxis. The process of fracture healing occurred nearly physiologically (shamlike). Notably, ALN hardly improved metaphyseal callus properties when assessed as osteoporosis prophylaxis, but to a lesser extent than E.
Literature
1.
go back to reference Savoca S, D’Agosta S, Lombardo G (2007) Evaluation of the hematochemical parameters and bone mineral density of women in physiological menopause treated with hormone replacement therapy with nomegestrol acetate and surgical menopause treated with estrogen replacement. Part II. Minerva Ginecol 59:215–222PubMed Savoca S, D’Agosta S, Lombardo G (2007) Evaluation of the hematochemical parameters and bone mineral density of women in physiological menopause treated with hormone replacement therapy with nomegestrol acetate and surgical menopause treated with estrogen replacement. Part II. Minerva Ginecol 59:215–222PubMed
2.
go back to reference Thompson DD, Simmons HA, Pirie CM, Ke HZ (1995) FDA guidelines and animal models for osteoporosis. Bone 17:125–133CrossRef Thompson DD, Simmons HA, Pirie CM, Ke HZ (1995) FDA guidelines and animal models for osteoporosis. Bone 17:125–133CrossRef
3.
go back to reference Curtis R, Goldhahn J, Schwyn R, Regazzoni P, Suhm N (2005) Fixation principles in metaphyseal bone—a patent based review. Osteoporos Int 16:54–64CrossRef Curtis R, Goldhahn J, Schwyn R, Regazzoni P, Suhm N (2005) Fixation principles in metaphyseal bone—a patent based review. Osteoporos Int 16:54–64CrossRef
4.
go back to reference Ahlborg HG, Johnell O, Turner CH, Rannevik G, Karlsson MK (2003) Bone loss and bone size after menopause. N Engl J Med 349:327–334CrossRefPubMed Ahlborg HG, Johnell O, Turner CH, Rannevik G, Karlsson MK (2003) Bone loss and bone size after menopause. N Engl J Med 349:327–334CrossRefPubMed
5.
go back to reference Iwaniec UT, Moore K, Rivera MF, Myers SE, Vanegas SM, Wronski TJ (2008) A comparative study of the bone-restorative efficacy of anabolic agents in aged ovariectomized rats. Osteoporos Int 18:351–362CrossRef Iwaniec UT, Moore K, Rivera MF, Myers SE, Vanegas SM, Wronski TJ (2008) A comparative study of the bone-restorative efficacy of anabolic agents in aged ovariectomized rats. Osteoporos Int 18:351–362CrossRef
6.
go back to reference Claes L, Veeser A, Göckelmann M, Simon U, Ignatius A (2009) A novel model to study metaphyseal bone healing under defined biomechanical conditions. Arch Orthop Trauma Surg 129:923–928CrossRefPubMed Claes L, Veeser A, Göckelmann M, Simon U, Ignatius A (2009) A novel model to study metaphyseal bone healing under defined biomechanical conditions. Arch Orthop Trauma Surg 129:923–928CrossRefPubMed
7.
go back to reference Johnell O, Kanis J (2005) Epidemiology of osteoporotic fractures. Osteoporos Int 16:3–7CrossRef Johnell O, Kanis J (2005) Epidemiology of osteoporotic fractures. Osteoporos Int 16:3–7CrossRef
8.
go back to reference Dennison E, Cooper C (2000) Epidemiology of osteoporotic fractures. Horm Res 54:58–63PubMed Dennison E, Cooper C (2000) Epidemiology of osteoporotic fractures. Horm Res 54:58–63PubMed
9.
go back to reference McCann RM, Colleary G, Geddis C, Clarke SA, Jordan GR, Dickson GR, Marsh D (2008) Effect of osteoporosis on bone mineral density and fracture repair in a rat femoral fracture model. J Orthop Res 26:384–393CrossRefPubMed McCann RM, Colleary G, Geddis C, Clarke SA, Jordan GR, Dickson GR, Marsh D (2008) Effect of osteoporosis on bone mineral density and fracture repair in a rat femoral fracture model. J Orthop Res 26:384–393CrossRefPubMed
10.
go back to reference Hao YL, Zhang G, Wang YS, Qin L, Hung WY, Leung K, Pei FX (2007) Changes of microstructure and mineralized tissue in the middle and late phase of osteoporotic fracture healing in rats. Bone 41:631–638CrossRefPubMed Hao YL, Zhang G, Wang YS, Qin L, Hung WY, Leung K, Pei FX (2007) Changes of microstructure and mineralized tissue in the middle and late phase of osteoporotic fracture healing in rats. Bone 41:631–638CrossRefPubMed
11.
go back to reference Augat P, Simon U, Liedert A, Claes L (2005) Mechanics and mechano-biology of fracture healing in normal and osteoporotic bone. Osteoporos Int 16:36–43CrossRef Augat P, Simon U, Liedert A, Claes L (2005) Mechanics and mechano-biology of fracture healing in normal and osteoporotic bone. Osteoporos Int 16:36–43CrossRef
12.
go back to reference Barrios C, Brostrom LA, Stark A, Walheim G (1993) Healing complications after internal fixation of trochanteric hip fractures: the prognostic value of osteoporosis. J Orthop Trauma 7:438–442CrossRefPubMed Barrios C, Brostrom LA, Stark A, Walheim G (1993) Healing complications after internal fixation of trochanteric hip fractures: the prognostic value of osteoporosis. J Orthop Trauma 7:438–442CrossRefPubMed
13.
go back to reference Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399–428CrossRefPubMed Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399–428CrossRefPubMed
14.
go back to reference Horwitz KB (2008) The year in basic science: update of estrogen plus progestin therapy for menopausal hormone replacement implicating stem cells in the increased breast cancer risk. Mol Endocrinol 22:2743–2750CrossRefPubMed Horwitz KB (2008) The year in basic science: update of estrogen plus progestin therapy for menopausal hormone replacement implicating stem cells in the increased breast cancer risk. Mol Endocrinol 22:2743–2750CrossRefPubMed
15.
go back to reference Tarakida A, Higuchi T, Mizunuma H (2007) Evidence of hormone replacement therapy for osteoporosis. Clin Calcium 18:1434–1441 Tarakida A, Higuchi T, Mizunuma H (2007) Evidence of hormone replacement therapy for osteoporosis. Clin Calcium 18:1434–1441
16.
go back to reference Cao Y, Mori S, Mashiba T, Westmore MS, Ma L, Sato M, Akiyama T, Shi L, Komatsubara S, Miyamoto K, Norimatsu H (2002) Raloxifene, estrogen and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res 17:2237–2246CrossRefPubMed Cao Y, Mori S, Mashiba T, Westmore MS, Ma L, Sato M, Akiyama T, Shi L, Komatsubara S, Miyamoto K, Norimatsu H (2002) Raloxifene, estrogen and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res 17:2237–2246CrossRefPubMed
17.
go back to reference Cao Y, Mori S, Mashiba T, Kaji Y, Manabe T, Iwata K, Miyamoto K, Komatsubara S, Yamamoto T (2007) 1Alpha, 25-dihydroxy-2beta(3-hydroxypropoxy)vitamin D3 (ED-71) suppressed callus modelling but did not interfere with fracture healing in rat femora. Bone 40:132–139CrossRefPubMed Cao Y, Mori S, Mashiba T, Kaji Y, Manabe T, Iwata K, Miyamoto K, Komatsubara S, Yamamoto T (2007) 1Alpha, 25-dihydroxy-2beta(3-hydroxypropoxy)vitamin D3 (ED-71) suppressed callus modelling but did not interfere with fracture healing in rat femora. Bone 40:132–139CrossRefPubMed
18.
go back to reference Alakangas A, Selander K, Mulari M, Halleen J, Lehenkari P, Mönkkönen J, Salo J, Väänänen K (2001) Alendronate disturbs vesicular trafficking in osteoclasts. Calcif Tissue Int 70:40–47CrossRefPubMed Alakangas A, Selander K, Mulari M, Halleen J, Lehenkari P, Mönkkönen J, Salo J, Väänänen K (2001) Alendronate disturbs vesicular trafficking in osteoclasts. Calcif Tissue Int 70:40–47CrossRefPubMed
19.
go back to reference Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: fracture Intervention trial research group. Lancet 348:1535–1541CrossRefPubMed Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: fracture Intervention trial research group. Lancet 348:1535–1541CrossRefPubMed
20.
go back to reference Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA (2004) Ten years’ experience with alendronate for osteoporosis in post menopausal women. N Engl J Med 350:1189–1199CrossRefPubMed Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA (2004) Ten years’ experience with alendronate for osteoporosis in post menopausal women. N Engl J Med 350:1189–1199CrossRefPubMed
21.
go back to reference Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ (1997) Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodelling in patients with osteoporosis. J Clin Invest 100:1475–1480CrossRefPubMed Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ (1997) Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodelling in patients with osteoporosis. J Clin Invest 100:1475–1480CrossRefPubMed
22.
go back to reference Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927–2938CrossRefPubMed Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927–2938CrossRefPubMed
23.
go back to reference van der Poest Clement E, van Engeland M, Ader H, Roos JC, Patka P, Lips P (2002) Alendronate in the prevention of bone loss after a fracture of the lower leg. J Bone Miner Res 17:2247–2255CrossRefPubMed van der Poest Clement E, van Engeland M, Ader H, Roos JC, Patka P, Lips P (2002) Alendronate in the prevention of bone loss after a fracture of the lower leg. J Bone Miner Res 17:2247–2255CrossRefPubMed
24.
go back to reference Van der Poest Clement E, Patka P, Vandormael K, Haarman H, Lips P (2000) The effect of alendronate on bone mass after distal forearm fracture. J Bone Miner Res 15:586–593CrossRefPubMed Van der Poest Clement E, Patka P, Vandormael K, Haarman H, Lips P (2000) The effect of alendronate on bone mass after distal forearm fracture. J Bone Miner Res 15:586–593CrossRefPubMed
25.
go back to reference Boskey AL, Spevak L, Weinstein RS (2008) Spectroscopic markers of bone quality in alendronate-treated postmenopausal women. Osteoporos Int 20:793–800CrossRefPubMed Boskey AL, Spevak L, Weinstein RS (2008) Spectroscopic markers of bone quality in alendronate-treated postmenopausal women. Osteoporos Int 20:793–800CrossRefPubMed
26.
go back to reference Guy JA, Shea M, Peter CP, Morrissey R, Hayes WC (1993) Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties. Calcif Tissue Int 53:283–288CrossRefPubMed Guy JA, Shea M, Peter CP, Morrissey R, Hayes WC (1993) Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties. Calcif Tissue Int 53:283–288CrossRefPubMed
27.
go back to reference Seidlova-Wuttke D, Hesse O, Jarry H, Christoffel V, Spengler B, Becker T, Wuttke W (2003) Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimifuga racemosa) extract: comparison with estradiol-17beta. Eur J Endocrinol 149:351–362CrossRefPubMed Seidlova-Wuttke D, Hesse O, Jarry H, Christoffel V, Spengler B, Becker T, Wuttke W (2003) Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimifuga racemosa) extract: comparison with estradiol-17beta. Eur J Endocrinol 149:351–362CrossRefPubMed
28.
go back to reference Wronski TJ, Lowry PL, Walsh CC, Ignaszewski LA (1985) Skeletal alterations in ovariectomized rats. Calcif Tiss Int 37:324–328CrossRef Wronski TJ, Lowry PL, Walsh CC, Ignaszewski LA (1985) Skeletal alterations in ovariectomized rats. Calcif Tiss Int 37:324–328CrossRef
29.
go back to reference Stuermer EK, Sehmisch S, Rack T, Wenda E, Seidlova-Wuttke D, Tezval M, Wuttke W, Frosch KH, Stuermer KM (2009) Estrogen and raloxifene improve metaphyseal fracture healing in the early phase of osteoporosis. A new fracture-healing model at the tibia in rat. Lang Arch Surg (in press) Stuermer EK, Sehmisch S, Rack T, Wenda E, Seidlova-Wuttke D, Tezval M, Wuttke W, Frosch KH, Stuermer KM (2009) Estrogen and raloxifene improve metaphyseal fracture healing in the early phase of osteoporosis. A new fracture-healing model at the tibia in rat. Lang Arch Surg (in press)
30.
go back to reference Rahn BA (1976) The fluorochrome sequence labeling of the bone. Nova Acta Leopold 44:249–255 Rahn BA (1976) The fluorochrome sequence labeling of the bone. Nova Acta Leopold 44:249–255
31.
go back to reference Stürmer EK, Seidlova-Wuttke D, Sehmisch S, Rack T, Wille J, Frosch KH, Wuttke W, Stürmer KM (2006) Standardized bending and breaking test for the normal and osteoporotic metaphyseal tibias of the rat: effect of estradiol, testosterone, and raloxifene. J Bone Miner Res 21:89–96CrossRefPubMed Stürmer EK, Seidlova-Wuttke D, Sehmisch S, Rack T, Wille J, Frosch KH, Wuttke W, Stürmer KM (2006) Standardized bending and breaking test for the normal and osteoporotic metaphyseal tibias of the rat: effect of estradiol, testosterone, and raloxifene. J Bone Miner Res 21:89–96CrossRefPubMed
32.
33.
go back to reference Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR histomorphometry nomenclature committee. J Bone Miner Res 2:595–610PubMedCrossRef Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR histomorphometry nomenclature committee. J Bone Miner Res 2:595–610PubMedCrossRef
34.
go back to reference Nikolaou VS, Efstathopoulos N, Kontakis G, Kanakaris NK, Giannoudis PV (2009) The influence of osteoporosis in femoral fracture healing time. Injury 40:663–668CrossRefPubMed Nikolaou VS, Efstathopoulos N, Kontakis G, Kanakaris NK, Giannoudis PV (2009) The influence of osteoporosis in femoral fracture healing time. Injury 40:663–668CrossRefPubMed
35.
go back to reference Bolander ME, Sabbagh R, Jeng C (1992) Estrogen treatment during fracture repair strengthens healing callus in an osteoporotic model. Trans Orthop Res Soc 17:138 Bolander ME, Sabbagh R, Jeng C (1992) Estrogen treatment during fracture repair strengthens healing callus in an osteoporotic model. Trans Orthop Res Soc 17:138
36.
go back to reference Schmidmaier G, Wildemann B, Bail H, Lucke M, Fuchs T, Stemberger A, Flyvberg A, Haas NP, Raschke M (2001) Local application of growth factors insulin-like growth factor-1 and transforming growth factor-β from a biodegradable poly (d, l-lactide) coating of osteosynthetic implants accelerated fracture healing in rats. Bone 28:341–350CrossRefPubMed Schmidmaier G, Wildemann B, Bail H, Lucke M, Fuchs T, Stemberger A, Flyvberg A, Haas NP, Raschke M (2001) Local application of growth factors insulin-like growth factor-1 and transforming growth factor-β from a biodegradable poly (d, l-lactide) coating of osteosynthetic implants accelerated fracture healing in rats. Bone 28:341–350CrossRefPubMed
37.
go back to reference Aspenberg P, Wermelin K, Tengwall P, Fahlgren A (2008) Additive effects of PTH and bisphoshonates on the bone healing response to metaphyseal implants in rats. Acta Orthop 79:111–115CrossRefPubMed Aspenberg P, Wermelin K, Tengwall P, Fahlgren A (2008) Additive effects of PTH and bisphoshonates on the bone healing response to metaphyseal implants in rats. Acta Orthop 79:111–115CrossRefPubMed
38.
go back to reference Morgan EF, Mason ZD, Bishop G, Davis AD, Wigner NA, Gerstenfeld LC, Einhorn TA (2008) Combined effects of recombinant human BMP-7 (rhBMP-7) and parathyroid hormone (1–34) in metaphyseal bone healing. Bone 43:1031–1038CrossRefPubMed Morgan EF, Mason ZD, Bishop G, Davis AD, Wigner NA, Gerstenfeld LC, Einhorn TA (2008) Combined effects of recombinant human BMP-7 (rhBMP-7) and parathyroid hormone (1–34) in metaphyseal bone healing. Bone 43:1031–1038CrossRefPubMed
39.
go back to reference Tsiridis E, Morgan EF, Bancroft JM, Song M, Kain M, Gerstenfeld L, Einhorn TA, Bouxsein ML, Tornetta P 3rd (2007) Effects of OP-1 and PTH in a new experimental model for the study of metaphyseal bone healing. J Orthop Res 25:1193–1203CrossRefPubMed Tsiridis E, Morgan EF, Bancroft JM, Song M, Kain M, Gerstenfeld L, Einhorn TA, Bouxsein ML, Tornetta P 3rd (2007) Effects of OP-1 and PTH in a new experimental model for the study of metaphyseal bone healing. J Orthop Res 25:1193–1203CrossRefPubMed
40.
go back to reference Manabe T, Mori S, Mashiba T, Cao Y, Kaji Y, Iwata K, Komatsubara S, Yamamoto T, Seki A, Norimatsu H (2009) Eel calcitonin (elcatonin) suppressed callus remodeling but did not interfere with fracture healing in the femoral fracture model of cynomolgus monkeys. J Bone Miner Metab 27:295–302CrossRefPubMed Manabe T, Mori S, Mashiba T, Cao Y, Kaji Y, Iwata K, Komatsubara S, Yamamoto T, Seki A, Norimatsu H (2009) Eel calcitonin (elcatonin) suppressed callus remodeling but did not interfere with fracture healing in the femoral fracture model of cynomolgus monkeys. J Bone Miner Metab 27:295–302CrossRefPubMed
41.
go back to reference Nancollas GH, Tang R, Phipps RJ, Henneman Z, Guide S, Wu W, Mangood A, Russell RG, Ebetino FH (2006) Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38:617–627CrossRefPubMed Nancollas GH, Tang R, Phipps RJ, Henneman Z, Guide S, Wu W, Mangood A, Russell RG, Ebetino FH (2006) Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38:617–627CrossRefPubMed
42.
go back to reference Cao YP, Mori S, Mashiba T (2007) Fracture callus under antiresorptive agent treatment evaluated by pQCT. In: Advanced bioimaging technologies in assessment of the quality of bone and scaffold materials techniques and applications. Springer, London, pp 553–566 Cao YP, Mori S, Mashiba T (2007) Fracture callus under antiresorptive agent treatment evaluated by pQCT. In: Advanced bioimaging technologies in assessment of the quality of bone and scaffold materials techniques and applications. Springer, London, pp 553–566
43.
go back to reference Kolios L, Sehmisch S, Daub F, Rack T, Tezval M, Stuermer KM, Stuermer EK (2009) Equol but not Genistein improves fracture healing in severe experimental osteoporotic bone in rats. Planta Med 75:459–465CrossRefPubMed Kolios L, Sehmisch S, Daub F, Rack T, Tezval M, Stuermer KM, Stuermer EK (2009) Equol but not Genistein improves fracture healing in severe experimental osteoporotic bone in rats. Planta Med 75:459–465CrossRefPubMed
Metadata
Title
Do Estrogen and Alendronate Improve Metaphyseal Fracture Healing When Applied as Osteoporosis Prophylaxis?
Authors
Leila Kolios
Ann Kristin Hoerster
Stephan Sehmisch
Marie Christin Malcherek
Thomas Rack
Mohammed Tezval
Dana Seidlova-Wuttke
Wolfgang Wuttke
Klaus Michael Stuermer
Ewa Klara Stuermer
Publication date
01-01-2010
Publisher
Springer-Verlag
Published in
Calcified Tissue International / Issue 1/2010
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-009-9318-7

Other articles of this Issue 1/2010

Calcified Tissue International 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.